文献速递脑血管病

急性缺血性卒中静脉溶栓后的生活质量:AcT随机对照试验结果

Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial.
PubMed 文献 · Stroke · 2024-01-26

AcT试验的辅助分析纳入1577例急性卒中患者,比较替奈普酶与阿替普酶静脉溶栓后90天健康相关生活质量(HRQOL)。两组EQ5D视觉模拟评分和指数值无显著差异(P=0.10)。患者报告的恢复至基线前功能与改良Rankin量表0-1分强相关(r=0.85)。

要点

  • 替奈普酶与阿替普酶静脉溶栓后90天EQ5D评分无显著差异(P=0.10)。
  • 年龄较大、卒中更严重、发病至穿刺时间更长与较低EQ5D评分相关。
  • 恢复至基线前功能与改良Rankin量表0-1分强相关(r=0.85)。

核心结论

  • 溶栓药物类型对急性卒中患者报告的总体HRQOL和EQ5D-5L指数值无差异效应,但研究中观察到HRQOL存在性别和年龄相关差异。

研究设计与样本

  • 数据来自AcT试验(阿替普酶对比替奈普酶)全部纳入患者,该试验为实用性、注册链接的随机试验,比较替奈普酶与阿替普酶。
  • 纳入意向性治疗分析1577例,其中1503例(95.3%)有完整EQ5D数据;769例(51.2%)接受替奈普酶,717例(47.7%)为女性。
  • 随机化后90天HRQOL采用5条目EuroQOL问卷(EQ5D)评估,包含5个条目和视觉模拟量表(VAS)。
  • EQ5D指数值基于加拿大常模采用时间权衡法从EQ5D条目估算。
  • 采用Tobit回归和分位数回归模型评估替奈普酶对比阿替普酶对EQ5D指数值和VAS评分的校正效应。

主要发现

  • 接受静脉替奈普酶者平均EQ5D VAS评分和EQ5D指数值未显著高于接受静脉阿替普酶者(P=0.10)。
  • 年龄较大(P<0.01)、美国国立卫生研究院卒中量表评估的卒中更严重(P<0.01)及发病至穿刺时间更长(P=0.004)与较低的EQ5D指数和VAS评分相关。
  • 患者报告的恢复至基线前功能与改良Rankin量表0-1分之间强相关(r=0.85[95%CI,0.81-0.89])。
  • 恢复至基线前功能与EQ5D指数中等相关(r=0.45[95%CI,0.40-0.49]),与EQ5D VAS评分中等相关(r=0.42[95%CI,0.37-0.46])。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent evidence from thrombolysis trials indicates the noninferiority of intravenous tenecteplase to intravenous alteplase with respect to good functional outcomes in patients with acute stroke. We examined whether the health-related quality of life (HRQOL) of patients with acute stroke differs by the type of thrombolysis treatment received. In addition, we examined the association between the modified Rankin Scale score 0 to 1 and HRQOL and patient-reported return to prebaseline stroke functioning at 90 days. METHODS: Data were from all patients included in the AcT trial (Alteplase Compared to Tenecteplase), a pragmatic, registry-linked randomized trial comparing tenecteplase with alteplase. HRQOL at 90-day post-randomization was assessed using the 5-item EuroQOL questionnaire (EQ5D), which consists of 5 items and a visual analog scale (VAS). EQ5D index values were estimated from the EQ5D items using the time tradeoff approach based on Canadian norms. Tobit regression and quantile regression models were used to evaluate the adjusted effect of tenecteplase versus alteplase treatment on the EQ5D index values and VAS score, respectively. The association between return to prebaseline stroke functioning and the modified Rankin Scale score 0 to 1 and HRQOL was quantified using correlation coefficient (r) with 95% CI. RESULTS: Of 1577 included in the intention-to-treat analysis patients, 1503 (95.3%) had complete data on the EQ5D. Of this, 769 (51.2%) were administered tenecteplase and 717 (47.7%) were female. The mean EQ5D VAS score and EQ5D index values were not significantly higher for those who received intravenous tenecteplase compared with those who received intravenous alteplase (P=0.10). Older age (P<0.01), more severe stroke assessed using the National Institutes of Health Stroke Scale (P<0.01), and longer stroke onset-to-needle time (P=0.004) were associated with lower EQ5D index and VAS scores. There was a strong association (r, 0.85 [95% CI, 0.81-0.89]) between patient-reported return to prebaseline functioning and modified Rankin Scale score 0 to 1 Similarly, there was a moderate association between return to prebaseline functioning and EQ5D index (r, 0.45 [95% CI, 0.40-0.49]) and EQ5D VAS scores (r, 0.42 [95% CI, 0.37-0.46]). CONCLUSIONS: Although there is no differential effect of thrombolysis type on patient-reported global HRQOL and EQ 5D-5L index values in patients with acute stroke, sex- and age-related differences in HRQOL were noted in this study. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03889249.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Sajobi TT, Arimoro OI, Ademola A, et al. Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial. Stroke. 2024. PMID: 38275116. doi:10.1161/STROKEAHA.123.044690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。